Mankind Pharma shares skid 4% amid block deal buzz
Three private equity funds, namely Chrys Capital, Capital Group, and Everbridge Partners, were reportedly looking to sell stakes worth $592 million in Mankind Pharma via the block deal.
Three private equity funds, namely Chrys Capital, Capital Group, and Everbridge Partners, were reportedly looking to sell stakes worth $592 million in Mankind Pharma via the block deal.
Mankind Pharma has reported 19.4% YoY rise in profit at ₹501.03 cr in Q2 FY24, while revenue from operations jumped 11.6% to ₹2,708.10 cr.
The pharma major reported 66% YoY growth in net profit at ₹494 crore, while sales rose 18% YoY to ₹2,579 crore in Q1FY24.
The Delhi-based healthcare company raised ₹4,326 crore in the country’s biggest IPO so far this year, which was subscribed 15.32 times on the back of strong response from QIBs.